Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: Systematic review and meta-analysis

BMJ

Volumn 336, Issue 7655, 2008, Pages 1227-1231

  Canonico, Marianne ^a,b   Plu Bureau, Geneviève ^a,c   Lowe, Gordon D O ^d   Scarabin, Pierre Yves ^a,c  

^a INSERM   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL; ESTRADIOL VALERATE; ESTROGEN; NORETHISTERONE ACETATE; PROGESTERONE;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG USE; HORMONE SUBSTITUTION; HUMAN; META ANALYSIS; MUTATION; OBESITY; POSTMENOPAUSE; PRIORITY JOURNAL; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM; CHEMICALLY INDUCED DISORDER; ESTROGEN THERAPY; FEMALE; INTRADERMAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK; RISK FACTOR;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 44849131373     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.39555.441944.BE     Document Type: Article

References (23)

1. Lowe G. Update on the cardiovascular risks of hormone replacement therapy. Women's Health 2007;3:87-97.
2. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008-12.
3. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 1987;9:1-30.
4. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
5. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
6. White H, Murin S. Is the current classification of venous thromboembolism acceptable? No. J Thromb Haemost 2004;2:2262-3.
7. Bertina RM. Genetic aspects of venous thrombosis. Eur J Obstet Gynecol Reprod Biol 2001;95:189-92.
8. Emmerich J, Rosendaal FR, Cattaneo M, Margaglione M, De Stefano V, Cumming T, et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism - pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost 2001;86:809-16.
9. Oger E. Incidence of venous thromboembolism: a community-based study in western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost 2000;83:657-60.
10. Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004;292:1573-80.
11. Miller J, Chan BK, Nelson HD. Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2002;136:680-90.
12. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002;288:872-81.
13. Gomes MP, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med 2004;164:1965-76.
14. Wu O, Robertson L, Langhorne P, Twaddle S, Lowe GD, Clark P, et al. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thromb Haemost 2005;94:17-25.
15. Lowe GD, Upton MN, Rumley A, McConnachie A, O'Reilly DS, Watt GC. Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein - a cross-sectional population survey. Thromb Haemost 2001;86:550-6.
16. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997;17:3071-8.
17. Oger E, Alhenc-Gelas M, Lacut K, Blouch MT, Roudaut N, Kerlan V, et al. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arterioscler Thromb Vasc Biol 2003;23:1671-6.
18. Conard J, Samama M, Basdevant A, Guy-Grand B, de Lignieres B. Differential AT III-response to oral and parenteral administration of 17 beta-estradiol. Thromb Haemost 1983;49:252.
19. Rosing J, Middeldorp S, Curvers J, Christella M, Thomassen LG, Nicolaes GA, et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet 1999;354:2036-40.
20. Hoibraaten E, Mowinckel MC, de Ronde H, Bertina RM, Sandset PM. Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial. Br J Haematol 2001;115:415-20.
21. Post MS, Christella M, Thomassen LG, van der Mooren MJ, van Baal WM, Rosing J, et al. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. Arterioscler Thromb Vasc Biol 2003;23:1116-21.
22. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002;360:942-4.
23. Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of the North American Menopause Society. Menopause 2007;14:168-82.